Aqsens Health and Research Teams from Nanjing and Shanghai Replicate Large-Scale Prostate Cancer Cohort Measurements in China
Aqsens Health’s team traveled to Shanghai in early July to conduct prostate cancer analyses in collaboration with research teams from Nanjing and Shanghai. The goal of the trip was to analyze a large, well-designed urine sample cohort using the latest phage-biosensors and protocols, replicating insights gained in Finland. The Aqsens team also trained the Chinese research teams to continue the work independently after their return. This collaboration combines Finnish biotech innovation with China’s research talent, advanced capabilities, and strong interest in urine-based analysis.
Aqsens Health starting pre-clinical trials for urinary tract cancer detection in China
Aqsens Health and its Chinese partner OG Pharmaceuticals have received funding for a joint prostate and bladder cancer pre-clinical and clinical research project in Jiangsu Province in China.
World Cancer Day 2022
Even though great advances have been made in cancer prevention, screening, diagnostics and care during the last decades, there are still huge differences and inequities in cancer care around the globe.
Improving prostate cancer screening quality and equality
Aqsens Health’s clinical advisor and Professor of Urology Antti Rannikko answeres a few questions about prostate cancer and prostate cancer screening.